Read the anns 06/12/23
This trial is not sponsored by IMU and not under IMU's control. The Uni London has chosen PD1-Vaxx over Keytruda. Could be because of costs or, as they said, the superior properties of PD1-Vaxx.
Again, market gives a damn, but the scientists approve it.
Investors follow the sp, scientists follow the science. Who will get it right in the end?
GLTA
Read the anns 06/12/23This trial is not sponsored by IMU and not...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
-0.002(2.78%) |
Mkt cap ! $519.7M | |||
| Open | High | Low | Value | Volume |
| 7.2¢ | 7.3¢ | 7.0¢ | $847.0K | 11.89M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 45 | 2225917 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.1¢ | 645158 | 16 |
View Market Depth
| Last trade - 12.11pm 20/05/2024 (20 minute delay) ? |
|
|||||
|
Last
7.0¢ |
Change
-0.002 ( 4.11 %) |
||||
| Open | High | Low | Volume | ||
| 7.2¢ | 7.3¢ | 7.0¢ | 4934398 | ||
| Last updated 12.30pm 20/05/2024 ? | |||||
| IMU (ASX) Chart |